Experience

Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]

July 25, 2025

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Asa Henin
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Jiqiang Lin
Associate, New York
Leina Verrier
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jean Park
Partner, New York
Aaron Pomeroy
Partner, Colorado
Michelle Garcia Schulman
Partner, Reston
Ellie Seber
Partner, Santa Monica
Marty Schenker
Senior Counsel , San Francisco
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Jeremy M. Exelbert
Associate, New York
Zack Gong
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Rebeca Kinslow
Associate, San Diego
Hilda Li
Associate, Hong Kong
Lunga Su
Associate, Shanghai
Novak Topalovic
Associate, San Diego
Tania Soris
Associate, New York
Monica Xu
Special Counsel, Shanghai
Sai Yarramalla
Associate, Palo Alto
Andy Zachrich
Associate, San Francisco
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York

Related Practices & Industries

Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics

May 19, 2025

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Navya Dasari
Associate, New York
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Rick Jantz
Associate, Santa Monica
Steve Przesmicki
Partner, San Diego
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
David Burns
Special Counsel, Washington, DC
Eileen Marshall
Partner, Washington, DC
Jonathan Rivinus
Partner, Colorado

Related Practices & Industries

Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA

April 8, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Caroline Vu
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Marc Suskin
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Rebecca Ross
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Jiqiang Lin
Associate, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology

December 23, 2024

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Asa Henin
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Jiqiang Lin
Associate, New York
Leina Verrier
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jean Park
Partner, New York
Aaron Pomeroy
Partner, Colorado
Michelle Garcia Schulman
Partner, Reston
Ellie Seber
Partner, Santa Monica
Marty Schenker
Senior Counsel , San Francisco
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Jeremy M. Exelbert
Associate, New York
Zack Gong
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Rebeca Kinslow
Associate, San Diego
Hilda Li
Associate, Hong Kong
Lunga Su
Associate, Shanghai
Novak Topalovic
Associate, San Diego
Tania Soris
Associate, New York
Monica Xu
Special Counsel, Shanghai
Sai Yarramalla
Associate, Palo Alto
Andy Zachrich
Associate, San Francisco
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York

Related Practices & Industries

View more

Admissions and credentials

New York